









Markets
/
Stocks
/
nasdaq-regn
/

Regeneron Pharmaceuticals Inc

REGN

759.180USD

+4.160+0.55%

Close 02/03, 16:00（ET）Quotes delayed by 15 min

79.79BMarket Cap

17.63P/E TTM



Regeneron Pharmaceuticals Inc

759.180

+4.160+0.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Regeneron Pharmaceuticals Inc

Currency: USD Updated: 2026-02-03

Key Insights

Regeneron Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 843.26.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Regeneron Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

14 / 159

Overall Ranking

50 / 4530

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Regeneron Pharmaceuticals Inc Highlights

StrengthsRisks

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Fairly Valued

The company’s latest PE is 17.63, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 93.48M shares, decreasing 2.27% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 126.00 shares of this stock.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

843.261

Target Price

+13.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-03

The current financial score of Regeneron Pharmaceuticals Inc is 9.28, ranking 10 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.88B, representing a year-over-year increase of 2.51%, while its net profit experienced a year-over-year increase of 7.97%.

Score

Industry at a Glance

Previous score

9.28

Change



Financials

8.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.76

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Regeneron Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-03

The current valuation score of Regeneron Pharmaceuticals Inc is 7.52, ranking 66 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 17.63, which is 69.14% below the recent high of 29.82 and 34.40% above the recent low of 11.56.

Score

Industry at a Glance

Previous score

7.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-03

The current earnings forecast score of Regeneron Pharmaceuticals Inc is 8.07, ranking 55 out of 159 in the Pharmaceuticals industry. The average price target is 767.00, with a high of 1057.00 and a low of 627.00.

Score

Industry at a Glance

Previous score

8.07

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

843.261

Target Price

+13.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Regeneron Pharmaceuticals Inc

REGN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-03

The current price momentum score of Regeneron Pharmaceuticals Inc is 7.25, ranking 67 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 814.07 and the support level at 711.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.23

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-3.067

Neutral

RSI(14)

51.507

Neutral

STOCH(KDJ)(9,3,3)

56.562

Neutral

ATR(14)

21.013

High Vlolatility

CCI(14)

64.372

Neutral

Williams %R

29.497

Buy

TRIX(12,20)

-0.069

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

751.244

Buy

MA10

754.851

Buy

MA20

761.233

Sell

MA50

757.254

Buy

MA100

682.625

Buy

MA200

620.534

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-03

The current institutional shareholding score of Regeneron Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 90.51%, representing a quarter-over-quarter decrease of 0.82%. The largest institutional shareholder is The Vanguard, holding a total of 9.02M shares, representing 8.73% of shares outstanding, with 0.91% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

9.00M

-4.02%

BlackRock Institutional Trust Company, N.A.

5.46M

-3.60%

State Street Investment Management (US)

4.69M

-2.91%

Dodge & Cox

Star Investors

4.55M

+18.94%

JP Morgan Asset Management

2.95M

+4.64%

Geode Capital Management, L.L.C.

2.54M

+2.87%

Invesco Capital Management (QQQ Trust)

2.32M

+6.12%

Putnam Investment Management, L.L.C.

2.15M

+5.78%

Capital World Investors

2.00M

+1.65%

Loomis, Sayles & Company, L.P.

1.98M

+1.98%

Risk Assessment

Currency: USD Updated: 2026-02-03

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Regeneron Pharmaceuticals Inc is 8.56, ranking 25 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.